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Abstract
Background: Human papillomavirus (HPV) is an important cause of head and neck squamous cell carcinoma
(HNSCC), especially in young people. These tumours overexpress p16 and respond well to treatment. The rapid
detection of HPV in patients with HNSCC may expedite treatment when p16 status is not immediately available.
Methods: Saliva-based DNA collection kits and nested polymerase chain reaction (PCR) were used to determine
the HPV status of 62 individuals with biopsy-proven HNSCC. Immunohistochemistry was used to determine tumour
p16 status.
Results: A total of 62 patients were included in the study. Twenty-nine samples (47%) were positive for HPV DNA,
the majority of which were high risk (HR) subtypes (79%). Patients who tested positive for HR HPV were more likely
to have a tumour arising in the oropharynx compared to a non-oropharyngeal site (74 vs 26%; p = 0.003). A positive
HR HPV saliva assay was 100% specific (95% CI 59–100%) and had a 100% positive predictive value (95% CI 75–100%)
for a p16 positive tumour arising in the oropharynx. In contrast, a negative HR HPV assay had a 96% negative predictive
value (95% CI 80–100%) for tumours arising in a non-oropharyngeal site. Independent of site, the saliva assay had a
sensitivity of 77% (95% CI 54–91%) and a specificity of 94% (95% CI 77–99%), respectively, for a p16 positive tumour.
Conclusion: We show that a saliva based assay is an effective method for detecting HPV in patients with HNSCC and
that a positive HR HPV test is highly specific for p16 positive tumours arising in the oropharynx. This simple and rapid
test could be used in cases where a biopsy of the primary tumour is not readily available.
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Background
Human papilloma virus (HPV) is a small, non-enveloped
DNA virus capable of infecting keratinocytes in the skin
or mucous membranes [1]. It is a ubiquitous virus with
some estimates suggesting that 80% of sexually active
women will be exposed to the virus during their lifetime.
In the vast majority of cases, the infection is cleared by
the immune system. However, exposure to a high-risk
HPV (HR HPV) subtype can lead to persistent infection
which, if left untreated, can progress to cancer [2]. The
link between high HR HPV and cancer is well docu-
mented in the cervix, vulva, vagina, penis, and anal canal
and recent studies have also shown that HR HPV is also
a risk factor for oropharyngeal squamous cell carcinoma
(HNSCC) [3]. Indeed, while HNSCC associated with
traditional risk factors such as smoking and alcohol have
been steadily on the decline for decades, cancers associ-
ated with HR HPV infection are on the rise, especially
among young people in industrialized countries [4, 5].
HPV infects the basal layer of the epithelium where it
can remain dormant for a variable period of time before
entering a productive phase. Clearance is T-cell medi-
ated and individuals with impaired cellular immunity
have a higher risk of progression to cancer [1]. When
expressed, the HPV oncogenes E6 and E7 induce the
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degradation of the tumour suppressors p53 and pRB,
which leads to uncontrolled cellular proliferation [6, 7].
Because pRB normally inhibits the expression of p16,
cells lacking pRB over-express p16 which can be de-
tected by immunohistochemistry and is commonly used
as a surrogate marker for HR HPV infection. HPV DNA
can be detected in saliva samples when cells are actively
producing viral particles or when infected cells die and
release the virus back into the saliva [8].
Patients with tumours over-expressing p16 respond
well to treatment and the rapid detection of HPV, espe-
cially a high risk subtype, in a patient with HNSCC may
expedite treatment [9]. Furthermore, the combination of
HR HPV DNA and p16 immunoreactivity may be a better
predictor of outcome than either marker alone [10]. With
those benefits in mind, we employed a novel saliva based
DNA assay in order to test the hypothesis that the presence
of HR HPV DNA predicts p16 positivity in patients with
biopsy-proven SCC of the head and neck.
Methods
Study population
This study was approved by the Ottawa Hospital Research
Ethics board. All patients who were seen at the Ottawa
Regional Cancer Centre (ORCC) with biopsy proven
squamous cell carcinoma of the upper aerodigestive
tract (excluding esophageal cancer) were approached to
participate in the study. Exclusion criteria included pa-
tients less than 18 years of age and those not able to
consent (due to dementia or other reasons) or those
unable to expectorate (poor performance status or very
advanced age).
Study design
Saliva samples were collected from consenting patients
using the Oragene®•DNA kit (OG-500) manufactured by
DNA Genotek, Inc. (www.dnagenotek.com). Saliva was
collected as per the manufacturer’s recommendation.
Each sample was coded with a study number and sent
for analysis at the Ottawa Hospital Research Institute.
The quality and quantity of extracted DNA was deter-
mined by β-globin specific PCR as described previously
[11]. Screening for the presence of HPV DNA was done
using a nested PCR approach consisting of the PGMY09/
11 primer set (primary PCR) and the GP5+/6+ primer set
(secondary PCR) as described previously [12, 13]. Briefly,
5 μL of each sample was amplified with PGMY09/11
primers (5 pmol each) and amplifications were performed
in a GeneAmp PCR System 9700 (Applied Biosystems,
Carlsbad, CA) using the following specifications: 95 °C for
2 min, 40 cycles of 95 °C for 1 min, 55 °C for 1 min, and
72 °C for 1 min. This was followed by a final extension of
10 min at 72 °C, and then storage at 4 °C. The secondary
PCR consisted of amplification of 2 μL of the primary
PCR product using the GP5+/6+ primers (5 pmol each).
Amplifications were performed in the same machine as
described above using the following specifications: 94 °C
for 2 min, and 40 cycles of 94 °C for 45 s, 48 °C for 4 s,
38 °C for 30 s, 42 °C for 5 s, 66 °C for 5 s, and 71 °C for
1.5 min. This was followed by a final extension of
10 min at 72 °C, and then storage at 4 °C. The PCR
products were electrophoresed using a 2% low-melting
point gel (NuSieve GTG Agarose), stained with ethidium
bromide and photographed under UV-transillumination.
The bands from any samples that were PCR positive were
isolated and purified using the Qiaquick Gel Extraction
Kit (Qiagen, Toronto, ON) following manufacturers pro-
tocol. The purified PCR products were then submitted for
automated DNA sequencing for forward and reverse se-
quencing (StemCore Sequencing Facility, Ottawa, ON).
The sequences were compared with HPV genomes de-
posited in the NCBI-GenBank using the BLAST pro-
gram (NCBI).
Immunohistochemistry
Immunohistochemical analysis for p16 (dilution 1:500,
clone SC-56330, Leica) was performed on formalin fixed
tissue sections using the BOND-MAX automated system
(Leica Microsystems, Wetzlar, German). Tissue sections
were subjected to epitope retrieval using a Bond epitope
retrieval solution appropriate for the primary antibody.
Statistical analysis
Statistical analysis was performed using SPSS 21 for
Windows (IBM, USA). For the purpose of this analysis,
the HPV subtypes were divided into low- and high-risk
categories according to the recent classification of the
International Agency for Research on Cancer. Specifi-
cally, the following HPV subtypes were defined as
high-risk based on their known carcinogenic potential
in humans: types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, and 59; all others were defined as low-risk [2].
Similarly, the primary tumour subsite was divided into
oropharynx (base of tongue and tonsil) and non-
oropharynx (all other sites). A Chi square or Fisher’s
exact test was used to compare categorical variables.
The sensitivity and specificity of the HPV test for pre-
dicting a p16 positive tumour was calculated with a
95% confidence interval. A test was considered statis-
tically significant when the p-value was <0.05.
Results
Out of the 70 patients invited to participate in the study,
62 gave consent. All participants who gave consent to
participate were included in the final analysis. The clinical
and pathological characteristics of the patients included in
this cohort are shown in Table 1. The majority of the pa-
tients in this study were male (74%) and the mean age at
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time of first pathological diagnosis was 58 years (range
32–83 years). Oral cavity and tonsil were the most com-
mon tumour sites (32% of cases each). Three patients pre-
sented with metastatic disease from an unknown primary
and one patient was diagnosed with carcinoma in situ.
The tumour stage varied greatly between patients but
patients with an oropharynx tumour (base of tongue or
tonsil) were much more likely to present with node posi-
tive disease compared to other sites (67 vs 22%; p = 0.001).
Immunohistochemistry for p16 was performed on 53
tumour samples; material was not available for immuno-
histochemical analysis in the other 9 cases. Of the 53
tumour samples tested, 22 (36%) were positive for p16
overexpression. All p16 positive tumours demonstrated
strong and diffuse nuclear and cytoplasmic staining. The
majority of tumours arising in the oropharynx were posi-
tive for p16 (71%) while only 5 tumours (17%) arising in a
non-oropharyngeal site were positive for p16. Non-
oropharyngeal and p16 positive tumours were located in
the lateral tongue, floor of mouth, soft palate, larynx, and
nasopharynx.
Of the 62 saliva samples tested, 29 (47%) were positive
for HPV DNA, the vast majority of which were a high-risk
type (79%). The specific subtypes isolated are shown in
Table 2. The most common subtype isolated was HPV-16
which was present in 29% of all patients tested and 62% of
saliva HPV positive patients. All other subtypes occurred
in a small minority of patients.
The clinical and pathological factors associated with a
positive HPV saliva test are shown in Table 3. Compared
to females, a higher proportion of males were observed
to have HPV DNA present in their saliva, although the
difference did not reach statistical significance (54 vs
25%; p = 0.08). Patients who tested positive for HPV
were more likely to present with node positive disease
(63 vs 34%; p = 0.010) as were patients with p16 positive
tumours (82 vs 13%; p < 0.001).
The relationship between HR HPV and p16 status is
shown in Table 4. Patients who tested positive for HR HPV
were significantly more likely to have a tumour arising in
the oropharynx compared to a non-oropharyngeal site
(74 vs 26%; p = 0.003). Of the 19 patients that tested
positive for HR HPV, 2 had tumours that were negative
for p16 and both of these tumours were located outside
of the oropharynx. Two of the five p16-positive tumours
arising outside of the oropharynx were also positive for
HR HPV. In our patient population a positive HR HPV
saliva assay was 100% specific (95% CI 59–100%) and had
a 100% positive predictive value (95% CI 75–100%) for a
p16 positive tumour arising in the oropharynx. In con-
trast, a negative HR HPV assay had a 96% negative pre-
dictive value (95% CI 80–100%) for tumours arising in a
non-oropharyngeal site. Independent of site, the saliva
assay had a sensitivity of 77% (95% CI 54–91%) and a
specificity of 94% (95% CI 77–99%), respectively, for a p16
positive tumour.
Discussion
Squamous cell carcinomas arising from head and neck
sites are divided into p16-positive and p16-negative
Table 1 Clinical and pathological characteristics of patients with





Oral cavity 20 (32)





Positive for HPV by saliva test 29 (47)
Low-risk HPV 6 (21)








Lymph node positive 27 (44)
Metastatic disease 4 (7)
p16 positive by immunohistochemistrya 22 (36)
ap16 status was only available for 53 patients
Table 2 HPV subtypes detected by saliva based DNA assay




6 1 1.6 3.4
16 18 29 62.1
27 1 1.6 3.4
33 2 3.2 6.9
56 1 1.6 3.4
58 1 1.6 3.4
59 1 1.6 3.4
66 1 1.6 3.4
72 1 1.6 3.4
73 1 1.6 3.4
76 1 1.6 3.4
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tumours in order to guide management and predict re-
sponse to treatment [9]. In this study we demonstrated
used a saliva based assay for detecting HPV DNA in pa-
tients with known HNSCC and found that this method
correlated with clinical and pathological features associ-
ated with p16 positive tumours. In addition, our collec-
tion method was extremely easy to use, well accepted by
patients and as the kits are stable at room temperature
for long periods of time, allowed for batching of samples
for future PCR testing.
The prevalence of HPV infection in our study popula-
tion was 47%, which is considerably higher than a re-
cent meta-analysis in which a prevalence of 21.95% was
documented among patients with HNSCC [14]. In this
study, however, HPV was only detected in tumour bi-
opsies and it is possible that our assay is more sensitive
at detecting low levels of HPV DNA compared to more
traditional tissue based methods which also utilize PCR.
For example, a saliva based assay could detect HPV DNA
present anywhere in the oral cavity or oropharynx. In con-
trast, a tissue based method would only detect HPV DNA
if the virus was present in the tumour cells sampled and
the prevalence would be lower if a significant proportion
of the tumours arose in the oral cavity.
The prevalence of HPV in our study was also higher in
men and in patients with tumours arising from the oro-
pharynx. This is consistent with previous studies in the
literature and re-iterates a different epidemiology of
HPV-related HNSCC patients compared with traditional
HNSCC usually arising in patients with a heavy smoking
and alcohol history [15–17]. Interestingly, in our study,
5 tumours arising from a non-oropharygeal sites were
positive for p16 over-expression and in 2 of these cases
the patients tested positive for salivary HR HPV. This
suggests that HPV may play an oncogenic role at least in
a subset of non-oropharyngeal HNSCC. Alternatively,
HR HPV may not contribute to the pathogenesis of the
tumour and the presence of the virus may be a result of
the high prevalence of HPV in our population and the
multiple risk factors shared among patients with oral
cavity and oropharynx SCC.
In our study, patients who tested positive for HR HPV
were more likely to present with lymph node positive
disease, a finding that is consistent with previous reports
that have shown that patients with p16 positive tumours
are more likely to present at an advanced stage compared
to patients with p16 negative tumours [18]. Paradoxically,
patients with p16 positive tumours have overall better
prognosis independent of stage [19].
Our assay detected several high-risk types of HPV in-
cluding 16, 33, 56, 58, and 59. Consistent with previous
reports, HPV 16 was the most common subtype. How-
ever, in contrast with HPV 18 being the second most
common subtype in the literature, in our sample HPV
33 was the only other subtype to be present in more
than a single case. This of course may be due to small
sample size. The relationship between HPV 16 and

























ap16 status was only available for 53 patients
Table 4 Relationship between HR HPV subtype and p16 over-expression
p16 status
HR HPV status Positive Negative p-value Sen (95% CI) Spe (95% CI) PPV (95% CI) NPV (95% CI)
Oropharynx Positive 13 0 0.001 76 (50–93) 100 (59–100) 100 (75–100) 64 (30–89)
Negative 4 7
Non-oropharynx Positive 5 2 0.002 80 (28–99) 93 (75–99) 67 (22–96) 96 (80–100)
Negative 1 25
Abbreviations: HR HPV High right human papillomavirus, Sen Sensitivity, Spe Specificity, PPV Positive predictive value, NPV Negative predictive value
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HNSCC varies between studies with some suggesting that
almost all HPV associated oropharyngeal SCC are positive
for HPV 16 [14]. Interestingly, p16 over-expression was
detected in all tumours arising from the oropharynx when
the patient was also positive for HPV 16. There are two
possible explanations for this finding. The first is that ex-
posure to HPV 16 results in a very high rate of persistent
infection. This would be consistent with recent findings
that HR HPV subtypes tend to be more likely to persist
than LR HPV subtypes [20, 21]. An alternative explanation
is that infection with HPV 16 results in a high rate of
cellular turnover and a high concentration of viral DNA
in saliva from affected patients.
Patients with tumours arising in the head and neck
frequently present with cervical lymphadenopathy and
no evidence of a primary tumour. In our study, HR HPV
was strongly associated with tumours arising in the oro-
pharynx. Specifically, a positive HR HPV assay was 100%
specific and had a 100% positive predictive value for p16
positive oropharyngeal tumours. In contrast, a positive
HR HPV assay had a 96% negative predictive value for
tumours arising from a non-oropharyngeal site. Such a
result would be particularly useful in the situation where
a primary tumour is not identified or an involved lymph
node is inaccessible. In this case, a positive HR HPV
assay could guide the surgeon to explore the oropharynx
and could potentially act as a surrogate marker in the
event that a primary tumour is not found and other
tissue is unavailable. Also, in situation where confirm-
ation of a base of tongue tumor is required, use of this
test could replace the need for a general anaesthetic for
tissue confirmation. Finally, several recent studies have
shown that a saliva-based assay can be used as a post-
treatment surveillance tool because the presence of HPV
DNA after treatment is associated with a higher risk of
recurrence [22–24]. While the sensitivity of our assay
was similar to these studies, it was significantly lower
than studies which measured HPV DNA directly in tu-
moral tissue [25]. As a result of its modest sensitivity
but high specificity, a saliva based assay is best suited for
confirming the presence of a clinically occult oropharyn-
geal tumour and monitoring for recurrence of an HPV
positive tumour after treatment.
Our study has several limitations. Firstly, we only
assessed patients with biopsy-proven SCC and thus the
prevalence of HPV in this population is not generalizable
to the general population. However, the purpose of this
study was to determine if the saliva based assay would cor-
relate with p16 status and to that end we required a popu-
lation with an established link to p16. Secondly, we did
not directly test the tumours for HPV, instead we relied
on p16 over-expression as a surrogate marker. The over-
expression of p16 in greater than 70% of cells (the method
used here in this study) has been shown however to have
a 93% sensitivity for HPV infection which would mean we
would miss no more than five HPV positive cases in a
study of our size [26]. Thirdly, three patients in our study
presented with a carcinoma of unknown primary and des-
pite rigorous investigations, the primary site was not iden-
tified. We ultimately decided to include these patients in
the study as these cases are widely believed to arise from
oropharyngeal lesions that disseminate early in their pro-
gression without forming a grossly identifiable primary le-
sion. And finally, p16 status was only available for 53 of
the 62 cases presented in our report. The patients in
whom we could not determine p16 status were included
in the description of HPV prevalence but excluded from
the analysis between HPV status and p16 over-expression.
While the unavailability of this data decreased the statis-
tical power of the study, it is unlikely that any of our most
salient conclusions would have been affected by the
addition a small number of additional cases [26].
Conclusion
Our study shows that a saliva based assay is an effective
method for detecting HPV in patients with HNSCC and
that a positive HR HPV test was highly specific for p16
positive tumours arising in the oropharynx.
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